• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Respir Investig . Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019

tetano

Editor, Senior Moderator
Respir Investig


. 2021 Apr 27;S2212-5345(21)00071-X.
doi: 10.1016/j.resinv.2021.04.002. Online ahead of print.
Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019


Takafumi Yamaya[SUP] 1 [/SUP], Eri Hagiwara[SUP] 1 [/SUP], Tomohisa Baba[SUP] 1 [/SUP], Takaaki Kitayama[SUP] 1 [/SUP], Kota Murohashi[SUP] 1 [/SUP], Katsuyuki Higa[SUP] 1 [/SUP], Yozo Sato[SUP] 1 [/SUP], Ryota Otoshi[SUP] 1 [/SUP], Erina Tabata[SUP] 1 [/SUP], Ryota Shintani[SUP] 1 [/SUP], Hiroko Okabayashi[SUP] 1 [/SUP], Satoshi Ikeda[SUP] 1 [/SUP], Takashi Niwa[SUP] 1 [/SUP], Atsuhito Nakazawa[SUP] 1 [/SUP], Tsuneyuki Oda[SUP] 1 [/SUP], Ryo Okuda[SUP] 1 [/SUP], Akimasa Sekine[SUP] 1 [/SUP], Hideya Kitamura[SUP] 1 [/SUP], Shigeru Komatsu[SUP] 1 [/SUP], Takashi Ogura[SUP] 2 [/SUP]



Affiliations

Abstract

Background: The serum Krebs von den Lungen-6 (KL-6) level is a predictive factor for acute respiratory distress syndrome (ARDS). The development of ARDS has been reported in patients with coronavirus disease 2019 (COVID-19). This study aimed to determine whether serum KL-6 levels are associated with mortality and severity in patients with COVID-19.
Methods: Among 361 Japanese patients with COVID-19 who were hospitalized at Kanagawa Cardiovascular and Respiratory Center between February 2020 and December 2020, 356 patients with data on serum KL-6 levels were enrolled and their medical records were retrospectively analyzed.
Results: A negative correlation was observed between KL-6 levels and the ratio of the arterial partial pressure of oxygen to the fraction of inspired oxygen on admission. The KL-6 levels on admission and the maximal KL-6 levels were higher in patients with severe disease (n = 60) than in those with nonsevere disease (n = 296). Furthermore, the maximal KL-6 levels were higher in nonsurvivors (n = 6) than in survivors (n = 350). In nonsurvivors, the KL-6 levels increased as the disease progressed. The optimal cutoff value of the maximal KL-6 level for discriminating between survivors and nonsurvivors was 684 U/mL, with a sensitivity of 83.3%, a specificity of 90.5%, and an area under the curve of 0.89.
Conclusions: The serum KL-6 level was associated with disease severity. Patients with KL-6 levels ?684 U/mL had a significantly poorer outcome than those with KL-6 levels <684 U/mL.

Keywords: Coronavirus disease 2019; Krebs von den Lungen-6; Prognosis; Severity.
 
Back
Top Bottom